skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 421  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
Material Type:
Article
Add to My Research

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

The New England journal of medicine, 2018-01, Vol.378 (4), p.354-369 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1702417 ;PMID: 29365309

Full text available

2
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients
Material Type:
Article
Add to My Research

Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients

The New England journal of medicine, 2019-04, Vol.380 (17), p.1606-1617 [Peer Reviewed Journal]

Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1812406 ;PMID: 30946553

Full text available

3
Screening and Treatment Program to Eliminate Hepatitis C in Egypt
Material Type:
Article
Add to My Research

Screening and Treatment Program to Eliminate Hepatitis C in Egypt

The New England journal of medicine, 2020-03, Vol.382 (12), p.1166-1174 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMsr1912628 ;PMID: 32187475

Full text available

4
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Material Type:
Article
Add to My Research

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

The New England journal of medicine, 2017-06, Vol.376 (22), p.2134-2146 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1613512 ;PMID: 28564569

Full text available

5
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Material Type:
Article
Add to My Research

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

The New England journal of medicine, 2015-12, Vol.373 (27), p.2608-2617 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1512612 ;PMID: 26575258

Full text available

6
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
Material Type:
Article
Add to My Research

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

The New England journal of medicine, 2015-12, Vol.373 (27), p.2618-2628 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1512614 ;PMID: 26569658

Full text available

7
Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication
Material Type:
Article
Add to My Research

Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication

Antimicrobial agents and chemotherapy, 2019-02, Vol.63 (2) [Peer Reviewed Journal]

Copyright © 2019 American Society for Microbiology. ;Copyright © 2019 American Society for Microbiology. 2019 American Society for Microbiology ;ISSN: 0066-4804 ;EISSN: 1098-6596 ;DOI: 10.1128/AAC.01389-18 ;PMID: 30455237

Full text available

8
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study
Material Type:
Article
Add to My Research

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

Clinical infectious diseases, 2017-07, Vol.65 (1), p.6-12 [Peer Reviewed Journal]

Copyright © 2017 Oxford University Press on behalf of the Infectious Diseases Society of America ;The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. ;Copyright Oxford University Press, UK Jul 1, 2017 ;The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2017 ;ISSN: 1058-4838 ;EISSN: 1537-6591 ;DOI: 10.1093/cid/cix260 ;PMID: 28369210

Full text available

9
Efficacy and Safety of Sofosbuvir‐Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation
Material Type:
Article
Add to My Research

Efficacy and Safety of Sofosbuvir‐Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation

American journal of transplantation, 2016-05, Vol.16 (5), p.1474-1479 [Peer Reviewed Journal]

Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons ;Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons. ;2016 the American Society of Transplantation and the American Society of Transplant Surgeons ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1600-6135 ;EISSN: 1600-6143 ;DOI: 10.1111/ajt.13518 ;PMID: 26587971

Full text available

10
Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis
Material Type:
Article
Add to My Research

Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis

Gastroenterology (New York, N.Y. 1943), 2017-07, Vol.153 (1), p.49-52 [Peer Reviewed Journal]

Attribution - NonCommercial ;ISSN: 0016-5085 ;EISSN: 1528-0012 ;DOI: 10.1053/j.gastro.2017.03.006 ;PMID: 28288791

Digital Resources/Online E-Resources

11
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis
Material Type:
Article
Add to My Research

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis

PLoS medicine, 2016-05, Vol.13 (5), p.e1002032-e1002032 [Peer Reviewed Journal]

COPYRIGHT 2016 Public Library of Science ;COPYRIGHT 2016 Public Library of Science ;2016 Public Library of Science. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. (2016) Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med 13(5): e1002032. doi:10.1371/journal.pmed.1002032 ;2016 World Health Organization 2016 World Health Organization ;2016 Public Library of Science. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. (2016) Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med 13(5): e1002032. doi:10.1371/journal.pmed.1002032 ;ISSN: 1549-1676 ;ISSN: 1549-1277 ;EISSN: 1549-1676 ;DOI: 10.1371/journal.pmed.1002032 ;PMID: 27243629

Full text available

12
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
Material Type:
Article
Add to My Research

The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication

Scientific reports, 2017-01, Vol.7 (1), p.40920-40920, Article 40920 [Peer Reviewed Journal]

Copyright Nature Publishing Group Jan 2017 ;Copyright © 2017, The Author(s) 2017 The Author(s) ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/srep40920 ;PMID: 28098253

Full text available

13
Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
Material Type:
Article
Add to My Research

Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic

Scientific reports, 2020-06, Vol.10 (1), p.9294-9294, Article 9294 [Peer Reviewed Journal]

The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-020-66440-9 ;PMID: 32518317

Full text available

14
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
Material Type:
Article
Add to My Research

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study

The Lancet infectious diseases, 2015-09, Vol.15 (9), p.1049-1054 [Peer Reviewed Journal]

Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Sep 2015 ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(15)00157-7 ;PMID: 26187031 ;CODEN: LANCAO

Full text available

15
Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)
Material Type:
Article
Add to My Research

Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)

Journal of antimicrobial chemotherapy, 2022-02, Vol.77 (3), p.758-766 [Peer Reviewed Journal]

The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2021 ;The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0305-7453 ;EISSN: 1460-2091 ;DOI: 10.1093/jac/dkab433 ;PMID: 34849957

Full text available

16
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives
Material Type:
Article
Add to My Research

Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives

Liver international, 2016-01, Vol.36 (S1), p.47-57 [Peer Reviewed Journal]

2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd ;2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. ;ISSN: 1478-3223 ;EISSN: 1478-3231 ;DOI: 10.1111/liv.13027 ;PMID: 26725897

Full text available

17
Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir
Material Type:
Article
Add to My Research

Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir

Clinical infectious diseases, 2015-10, Vol.61 (8), p.1304-1306 [Peer Reviewed Journal]

Copyright © 2015 Oxford University Press on behalf of the Infectious Diseases Society of America ;The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. ;ISSN: 1058-4838 ;EISSN: 1537-6591 ;DOI: 10.1093/cid/civ474 ;PMID: 26082511

Full text available

18
Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients
Material Type:
Article
Add to My Research

Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients

The New England journal of medicine, 2016-11, Vol.375 (21), p.2106-2108 [Peer Reviewed Journal]

Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMc1611829 ;PMID: 27959735

Full text available

19
An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens
Material Type:
Article
Add to My Research

An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens

The American journal of gastroenterology, 2016-06, Vol.111 (6), p.808-816 [Peer Reviewed Journal]

Copyright Nature Publishing Group Jun 2016 ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.1038/ajg.2016.99 ;PMID: 27021197

Full text available

20
Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment
Material Type:
Article
Add to My Research

Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment

Postgraduate medical journal, 2022-07, Vol.98 (1161), p.509 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;EISSN: 1469-0756 ;PMID: 37066509

Full text available

Results 1 - 20 of 421  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (399)

Refine My Results

Creation Date 

From To
  1. Before 2015  (3)
  2. 2015 To 2016  (142)
  3. 2017 To 2018  (117)
  4. 2019 To 2021  (105)
  5. After 2021  (55)
  6. More options open sub menu

Resource Type 

  1. Articles  (420)
  2. magazinearticle  (1)
  3. More options open sub menu

Language 

  1. English  (419)
  2. Japanese  (45)
  3. Portuguese  (5)
  4. Spanish  (3)
  5. More options open sub menu

Searching Remote Databases, Please Wait